Invasive Saccharomyces Infection: A Comprehensive Review
The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Saccharomyces cerevisiae (also known as "baker's yeast" or "brewer's yeast") is mostly considered to be an occasional digestive commensal. However, since the 1990s, there have been a growing number of reports about its implication as an etiologic agent of invasive infection. A particular feature of such infections is their association with a probiotic preparation of Saccharomyces boulardii (a subtype of S. cerevisiae) for treatment various diarrheal disorders. METHODS: We collected published case reports, through May 2005, of invasive Saccharomyces infection by use of a Medline query. Epidemiological and clinical charts and therapeutic strategies were analyzed. RESULTS: We found 92 cases of Saccharomyces invasive infection. Predisposing factors were similar to those of invasive candidiasis, with intravascular catheter and antibiotic therapy being the most frequent. Blood was the most frequent site of isolation (for 72 patients). S. boulardii accounted for 51.3% of fungemias and was exclusively isolated from blood. Compared with patients infected with S. cerevisiae, patients infected with S. boulardii were more frequently immunocompetent and had a better prognosis. Saccharomyces invasive infection was clinically indistinguishable from an invasive candidiasis. Overall, S. cerevisiae clinical isolates exhibited low susceptibility to amphotericin B and azole derivatives. However, global outcome was favorable in 62% of the cases. Treatment with intravenous amphotericin B and fluconazole, in combination with central vascular catheter removal, were effective therapeutic options. CONCLUSION: Saccharomyces organisms should now be added to the growing list of emerging fungal pathogens. Special caution should be taken regarding the use of S. boulardii probiotic preparations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple cases of disseminated infection have been identified in apparent association with this probiotic, particularly in immune-suppressed individuals (39).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [39]
In the citing paper
“In a few case studies, however, S. cerevisiae has been implicated in catheter-associated infections with mixed-species biofilms in patients in intensive care units (ICUs)”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [50]
In the citing paper
“and it is able to form a thin biofilm consisting of round, budding yeast-form cells and pseudohyphal cells in vitro (26, 50, 128, 164).”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [50]
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“We only considered proven infection, based on the definitions of the Invasive Fungal Infection Cooperative Group of the European Organization for Research and Treatment of Cancer–Mycosis Study Group of the National Institute of Allergy and Infectious Diseases cooperative group [19]: fungemia, isolation from normally s…”
MethodNEW YORK STATE JOURNAL OF MEDICINE.
(1901) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1901.02470020041007 · Cited by 1,472
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Medical Mycology. The Pathogenic Fungi and Pathogenic Actinomycetes.
(1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-4-514_1 · Cited by 847
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 1×
“Despite this spectrum of susceptibility, a favorable outcome was observed in 63% of cases revealed in our literature search, which is a slightly higher percentage than that reported for cases of invasive candidiasis [87].”
ResultProtection from gastrointestinal diseases with the use of probiotics
Marteau, P. R., Vrese, M. D., Cellier, C. J., & Schrezenmeir, J. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.430s · Cited by 596
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462 · cited 1×
“35[77] 76 years, F DNA fingerprinting Diabetes, heart surgery No Yes Yes Yes FLU NS Death 36 [771 72 years, F DNA fingerprinting Heart surgery No Yes Yes Yes None NS Death 37 [77] 74 years, F DNA fingerprinting Rheumatoid arthritis, corticosteroid therapy, heart surgery NS No Yes Yes FLU NS Death”
BackgroundFUNGAL ENDOCARDITIS: ANALYSIS OF 24 CASES AND REVIEW OF THE LITERATURE
EUBINSTE1N, E., NOKIEGA, E. R., SIMBEEKOFF, M. S., HOLZMAN, E., & RAHAL, J. J. (1975) · Medicine · doi:10.1097/00005792-197507000-00003 · Cited by 275 · cited 1×
“1 [231 54 years, F Blood Urine Diphtheroids Valvular prosthesis No Yes Yes AmB Yes Favorable 2 [24] 38 years, M .”
BackgroundNew Spectrum of Fungal Infections in Patients with Cancer
Anaissie, E., Bodey, G. P., Kantarjian, H., Ro, J., Vartivarian, S. E., Hopfer, R., Hoy, J., & Rolston, K. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.369 · Cited by 259
Possible Role of Catheters in Saccharomyces boulardii Fungemia
Hennequin, C., Kauffmann-Lacroix, C., Jobert, A., Viard, J. P., Ricour, C., Jacquemin, J. L., & Berche, P. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050003 · Cited by 253 · cited 5×
“Hand transmission has been suggested in these latter cases [5].”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 9
- 2001, 11, 19
- Rubinstein, 1975, Medicine, 54, 331
- Eschete, 1980, Archives of Internal Medicine, 140, 1539, 10.1001/archinte.1980.00330220085032 · doi:10.1001/archinte.1980.00330220085032
- 1997, Bulletin de la Soci t de pathologie exotique (1990), 90, 307
- Pavese, 1999, Pathologie-biologie, 47, 579
- Feld, 1982, The Journal of Rheumatology, 9, 637
- Kirsch, 1999, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 34, 229
- Zunic, 1991, Th rapie, 46, 498
- Pletincx, 1995, Journal of pediatric gastroenterology and nutrition, 21, 113, 10.1097/00005176-199507000-00022 · doi:10.1097/00005176-199507000-00022 · Paper page
Cited by
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
“boulardii has, however, been associated with fungemia in immunocompromised patients and in patients with central venous lines, and it should be avoided in critically ill patients.(227) There is no compelling evidence that other probiotics are useful in the prevention or treatment of recurrent CDI.”
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
“probiotics such as Saccharomyces boulardii in debilitated or immunocompromised patients [134,135].”
BackgroundCandida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Metadata
- Authors
- Enache-Angoulvant, A., & Hennequin, C.
- Affiliations
- Hôpital Tenon (FR)
- Corresponding author
- Hennequin, C.
- ORCID
- Hennequin, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-01
- Volume
- 41
- Issue
- 11
- Pages
- 1559-1568
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168407031
- Cited by
- 369
- References
- 88
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 14 · 2021: 17 · 2020: 24 · 2019: 19 · 2018: 23 · 2017: 34 · 2016: 19 · 2015: 23 · 2014: 14 · 2013: 23 · 2012: 18
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- Saccharomyces cerevisiae, Saccharomyces boulardii, invasive candidiasis, fungemia, emerging fungal pathogens, amphotericin B susceptibility, fluconazole, central venous catheters, antibiotic therapy, immunocompetent patient
- MeSH terms
- Female, Humans, Male, Mycoses, Risk Factors, Saccharomyces
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.